Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022

Insmed to Host Third Quarter 2022 Financial Results Conference Call on Thursday, October 27, 2022

PR Newswire

BRIDGEWATER, N.J., Oct. 13, 2022

BRIDGEWATER, N.J., Oct. 13, 2022 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will release its third quarter 2022 financial results on Thursday, October 27, 2022.

Insmed management will host a conference call for investors beginning at 8:30 a.m. ET on Thursday, October 27, 2022 to discuss the financial results and provide a business update.

Shareholders and other interested parties may participate in the conference call by dialing (844) 200-6205 (U.S.) or (929) 526-1599 (international) and referencing access code 889963. The call will also be webcast live on the company's website at www.insmed.com.

A replay of the conference call will be accessible approximately 2 hours after its completion through November 26, 2022, by dialing (866) 813-9403 (U.S.) or (+44) 204-525-0658 (international) and referencing access code 035584. A webcast of the call will also be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
[email protected]

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-third-quarter-2022-financial-results-conference-call-on-thursday-october-27-2022-301643047.html

SOURCE Insmed Incorporated

Copyright CNW Group 2022

Disclaimer :: Use of this site is subject to, and your continued use constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information. INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion; however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR® or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment. Users should always consult with and obtain advice from their professional licensed financial advisor, including their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment or trading securities do so with caution. Users should perform full due diligence and investigate any security fully before making an investment or before the execution of a security trade based upon information learned through INK. Investors should obtain annual reports and other company information to complete their own due diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this website. On this site, there may be third party content, content from authors or links to third-party sites or pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI® is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.

Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.